Induction of cytotoxic T cell response against HCA661 positive cancer cells through activation with novel HLA-A∗0201 restricted epitopes
| Autor: | Paul Ha-Sang Pang, Ray Chun-Fai Chan, Yong Xie, Fion Wan-Yee Sin, Kin-Tak Chan, Zhihong Guo, Luigi Ying-Wai Tse, Ying-Kit Cheung |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Fetal Proteins
Cancer Research Carcinoma Hepatocellular Cell Survival Cell Adhesion Molecules Neuronal medicine.medical_treatment T cell Enzyme-Linked Immunosorbent Assay Lymphocyte Activation Epitope Interferon-gamma Interleukin 21 Antigen Antigens CD Cell Line Tumor HLA-A2 Antigen medicine Humans Cytotoxic T cell Antigen-presenting cell HLA-A Antigens Immunodominant Epitopes Chemistry Liver Neoplasms Computational Biology Immunotherapy Dendritic cell Molecular biology medicine.anatomical_structure Oncology Feasibility Studies Epitope Mapping T-Lymphocytes Cytotoxic |
| Zdroj: | Cancer Letters. 256:178-185 |
| ISSN: | 0304-3835 |
| DOI: | 10.1016/j.canlet.2007.06.002 |
| Popis: | HCA661 is a cancer-testis (CT) antigen frequently expressed in human hepatocellular carcinoma (HCC). To search for immunogenic peptides of HCA661, bioinformatics analysis and CD8(+) T cell IFN-gamma ELISPOT assay were employed, and two HLA-A *0201 restricted peptides, H110 and H246, were identified. These two HCA661 peptides are naturally processed in dendritic cells (DCs) and when used for DCs loading, they are sufficient to prime autologous CD8(+) T cells to elicit cytotoxic response against HCA661(+) human cancer cells. The HCA661 peptides, H110 and H246, are hence attractive candidates for human cancer immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect